# Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

> **NCT04618081** · — · COMPLETED · sponsor: **Celgene** · enrollment: 151 (actual)

## Conditions studied

- Lymphoma Nonhodgkin

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04618081
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-17
- **Primary completion:** 2025-03-27
- **Final completion:** 2025-03-27
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04618081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04618081, "Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04618081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*